About the study
Olanzapine is an anti-psychotic which is often prescribed for schizophrenia, schizophreniform disorder or bipolar disorder. One of the common side effects is weight gain, which can lead to people not taking their medication. This study is looking at an alternative drug called ALK 3831 to see whether it reduces weight gain and can therefore be used as an alternative to olanzapine. The aim is to improve medication adherence.
Who can take part
We are looking for people aged between 18 to 40 years old who have a diagnosis of schizophrenia, schizophreniform disorder or bipolar disorder and have not taken olanzapine before.
What will I have to do
The study lasts for approximately 20 weeks. This is split into a 4 week screening period, a 12 week treatment phase and a 4 week follow up.
You will be asked to make regular visits over a 12 week period to our Abraham Cowley Unit based on the St Peter's Hospital site in Cherstey. We will carry out physical examinations, take blood and urine samples, test your vital signs (such as blood pressure, pulse and temperature), conduct ECGs and check your weight.
Find out more
We would really like to hear from you if you fit the description above and are interested in taking part to help in the search for alternative anti-psychotics that reduce weight gain and improve medication adherence. Please email us on email@example.com or call us on 01932 722 247.